Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $93.42M in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
Immunic USD 0 0 Jun/2024
Incyte USD 29.41M 785K Mar/2026
Merck USD 46.67B 77M Mar/2026